JP2010523592A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523592A5
JP2010523592A5 JP2010502317A JP2010502317A JP2010523592A5 JP 2010523592 A5 JP2010523592 A5 JP 2010523592A5 JP 2010502317 A JP2010502317 A JP 2010502317A JP 2010502317 A JP2010502317 A JP 2010502317A JP 2010523592 A5 JP2010523592 A5 JP 2010523592A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
endosialin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010502317A
Other languages
English (en)
Japanese (ja)
Other versions
JP5825784B2 (ja
JP2010523592A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/059374 external-priority patent/WO2008124570A1/en
Publication of JP2010523592A publication Critical patent/JP2010523592A/ja
Publication of JP2010523592A5 publication Critical patent/JP2010523592A5/ja
Application granted granted Critical
Publication of JP5825784B2 publication Critical patent/JP5825784B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010502317A 2007-04-05 2008-04-04 エンドシアリンのリガンドへの結合を阻害する方法 Active JP5825784B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US60/910,362 2007-04-05
US98002607P 2007-10-15 2007-10-15
US60/980,026 2007-10-15
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013041304A Division JP2013150618A (ja) 2007-04-05 2013-03-01 エンドシアリンのリガンドへの結合を阻害する方法

Publications (3)

Publication Number Publication Date
JP2010523592A JP2010523592A (ja) 2010-07-15
JP2010523592A5 true JP2010523592A5 (enExample) 2011-09-15
JP5825784B2 JP5825784B2 (ja) 2015-12-02

Family

ID=39714208

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010502317A Active JP5825784B2 (ja) 2007-04-05 2008-04-04 エンドシアリンのリガンドへの結合を阻害する方法
JP2013041304A Pending JP2013150618A (ja) 2007-04-05 2013-03-01 エンドシアリンのリガンドへの結合を阻害する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013041304A Pending JP2013150618A (ja) 2007-04-05 2013-03-01 エンドシアリンのリガンドへの結合を阻害する方法

Country Status (20)

Country Link
US (4) US7807382B2 (enExample)
EP (2) EP2620451B1 (enExample)
JP (2) JP5825784B2 (enExample)
KR (1) KR101529334B1 (enExample)
CN (1) CN101918446B (enExample)
AU (1) AU2008237296B2 (enExample)
BR (1) BRPI0809665B8 (enExample)
CA (1) CA2682726C (enExample)
CY (2) CY1115370T1 (enExample)
DK (2) DK2620451T3 (enExample)
ES (2) ES2606906T3 (enExample)
HR (2) HRP20140266T1 (enExample)
HU (1) HUE031269T2 (enExample)
LT (1) LT2620451T (enExample)
MX (1) MX2009010701A (enExample)
PL (2) PL2620451T3 (enExample)
PT (2) PT2137217E (enExample)
RS (2) RS55447B1 (enExample)
SI (2) SI2137217T1 (enExample)
WO (1) WO2008124570A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116451A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
CA2682726C (en) 2007-04-05 2017-05-09 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US20130305396A1 (en) 2010-09-29 2013-11-14 Luigi Grasso Engineered human endosialin-expressing rodents
AU2013240281B2 (en) * 2012-03-30 2017-12-21 Eisai R&D Management Co., Ltd. TEM-1 diagnostic antibodies
US9783610B2 (en) * 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
WO2014164544A1 (en) 2013-03-09 2014-10-09 Baylor College Of Medicine Vascular-targeted t-cell therapy
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR20220003529A (ko) 2019-04-01 2022-01-10 어플라이드 테라퓨틱스 인크. 알도스 리덕타제의 억제제
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
ATE244888T1 (de) * 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
CA2185116A1 (en) * 1994-03-08 1995-09-14 Thomas P. Wallace Recombinant humanized anti-fb5 antibodies
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
CA2355337A1 (en) 1998-09-09 2000-03-16 U.S. Army Institute Of Surgical Research Method for monitoring arterial oxygen saturation
AU2001250381A1 (en) * 2000-03-15 2001-09-24 Epigenomics Ag Diagnosis of diseases associated with tumor suppressor genes and oncogenes
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
JP5036119B2 (ja) 2001-01-15 2012-09-26 モーフオテク・インコーポレーテツド ミスマッチ修復の化学阻害剤
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) * 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
EP1576131A4 (en) * 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
WO2004048938A2 (en) * 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
KR20060003860A (ko) * 2003-03-04 2006-01-11 기린 비루 가부시키가이샤 내피 세포 특이적 항체 및 그의 용도
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
DE602005025659D1 (enExample) * 2004-09-23 2011-02-10 Guerbet Sa
ATE476449T1 (de) 2004-12-03 2010-08-15 Morphotek Inc Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
EP2295601A1 (en) * 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
WO2006116451A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
BRPI0620695A2 (pt) * 2005-12-16 2011-11-22 Genentech, Inc método para tratar um tumor do tipo glioma, métodos de prognóstico e/ou diagnóstico de glioma, método de monitoramento ou diagnóstico, método para inibir o tamanho ou crescimento de um tumor do tipo glioma, métodos para tratar terapeuticamente, método para determinar o nìvel de expressão de marcadores determinantes de glioma ("gdm") de pn, prolif ou mes, método para prognosticar o tempo de sobrevida, método para diagnosticar a severidade de um tumor do tipo glioma e uso
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
EP2041307A2 (en) * 2006-07-13 2009-04-01 Siemens Healthcare Diagnostics GmbH Prediction of breast cancer response to taxane-based chemotherapy
EP2049713A4 (en) * 2006-07-21 2010-06-16 Univ Alberta tissue rejection
WO2008021288A2 (en) 2006-08-11 2008-02-21 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
US20110119776A1 (en) 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
CA2682726C (en) * 2007-04-05 2017-05-09 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
JP5769417B2 (ja) 2007-08-16 2015-08-26 ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ 腫瘍細胞由来微小胞
CN105734128B (zh) * 2008-02-01 2021-05-18 总医院有限公司 微泡在医学疾病和病况的诊断、预后以及治疗中的用途
US20110117551A1 (en) 2008-02-19 2011-05-19 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Similar Documents

Publication Publication Date Title
JP2010523592A5 (enExample)
JP2012523848A5 (enExample)
JP2013544756A5 (enExample)
JP2018504890A5 (enExample)
HRP20190762T1 (hr) Protutijela koja se vežu prvenstveno na izvanstaničnu domenu 4 ljudskog csf1r i njihova uporaba
JP2009518039A5 (enExample)
JP2013545455A5 (enExample)
JP2013506428A5 (enExample)
IL273424B1 (en) Novel bispecific cd3/cd19 polypeptide complexes
JP2010538608A5 (enExample)
JP2016507523A5 (enExample)
JP2010533498A5 (enExample)
RU2018128414A (ru) Новое psma-связывающее антитело и его применения
JP2012525854A5 (enExample)
RU2009126766A (ru) Антитела человека к дельта-подобному лиганду-4 человека
JP2017522892A5 (enExample)
JP2016512551A5 (enExample)
JP2018510636A5 (enExample)
JP2016512521A5 (enExample)
JP2015533853A5 (enExample)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2018507188A5 (enExample)
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2005518336A5 (enExample)
RU2008129111A (ru) Антитела к ox40l и способы их применения